This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Basal Insulin/GLP-1 RA Combination: Therapeutic Synergy for Tight Glycemic Control

Basal Insulin/GLP-1 RA Combination: Therapeutic Synergy for Tight Glycemic Control


Expert Perspective

Time to Complete

1 hour


March 23, 2017


March 23, 2018
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Sanofi US

Program Description

The current recommendations for the treatment of patients with type 2 diabetes mellitus (T2DM) emphasize the need to target multiple pathophysiologic targets of the disease and, therefore, 2 or more agents may be needed to achieve the optimal hemoglobin A1C (A1C) goal. To that end, clinicians should recommend agents that have complementary and additive mechanisms of action, such as basal insulin plus a glucagon-like peptide-1 receptor agonist (GLP-1 RA), which together address both fasting plasma glucose (FPG) and postprandial glocose (PPG) while minimizing adverse effects such as hypoglycemia. Recent clinical trials have also documented the benefits of these 2 injectable medications delivered in a fixed-ratio-delivery injectable pen, which may provide greater convenience for patients and better adherence.

Intended Audience

Diabetologists, endocrinologists, internists, family/general practitioners, nurse practitioners, physician assistants, certified diabetes educators, and other clinicians involved in the care of patients with diabetes

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Identify the advantages and limitations of GLP-1 RAs
  • Explain the advantages and limitations of basal insulin
  • Compare the clinically relevant characteristics of GLP-1 RAs
  • Assess the advantages and limitations of treating T2DM with a fixed-ratio combination of insulin plus a short-acting GLP-1 vs administering those agents as separate injections
  • Individualize T2DM management strategies to meet patients’ treatment goals with consideration for both FPG and PPG, to minimize adverse effects of treatment, and to promote adherence

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.


Vivian Fonseca, MD
Professor of Medicine and Pharmacology
Tullis-Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA

Dr. Fonseca has received research grants from Abbott, Asahi Kasei Pharma America, Eli Lilly, GI Dynamics, Inc., Gilead Sciences, Inc., and Novo Nordisk. He has received consultant fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Nestlé Health Science - Pamlab, Inc., and Sanofi-Aventis.

Guillermo Umpierrez, MD
Professor of Medicine
Emory University
Section Head
Diabetes and Endocrinology
Grady Health System
Atlanta, GA

Dr. Umpierrez has received research grants from AstraZeneca, Merck & Co., Novo Nordisk, and Sanofi US and consulting fees from Sanofi US.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of HME and Sanofi US. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue